Glucocorticoid receptor changes its cellular location with breast cancer development

Histology and Histopathology

Volumn 23, Issue 1, 2008, Pages 77-85

  Conde, Isabel ^a   Paniagua, Ricardo ^a   Fraile, Benito ^a   Lucio, Javier ^a   Arenas, Maria I ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Breast cancer; COX 2; GR; MR

Indexed keywords

CYCLOOXYGENASE 2; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; PTGS2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST; BREAST TUMOR; CARCINOMA IN SITU; FEMALE; FIBROADENOMA; HUMAN; HYPERPLASIA; LUNG CARCINOMA; METABOLISM; METAPLASIA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CYCLOOXYGENASE 2; FEMALE; FIBROADENOMA; HUMANS; HYPERPLASIA; METAPLASIA; MIDDLE AGED; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID;

EID: 35748929961     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Amsterdam A., Tajima K. and Sasson R. (2002). Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem. Pharmacol. 64, 843-850.
2. Bhargava A. and Pearce D. (2004). Mechanisms of mineralocorticoid action: determinants of receptor specificity and actions of regulated gene products. Trends. Endocrinol. Metab. 15, 147-153.
3. Boland G.P., Butt I.S., Prasad R., Knox W.F. and Bundred N.J. (2004). COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer 90, 423-429.
4. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I. and Schmitt F.C. (2002). Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J. Clin. Pathol. 55, 429-434.
5. Dickson R.B. and Lippman M.E. (1988). Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat. Res. 40, 119-165.
6. Evans-Storms R.B. and Cidlowski J.A. (2000). Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: the role of nuclear factor-kappaB. Endocrinology 141, 1854-1862.
7. Ewing T.M., Murphy L.J., Ng M-L., Pang G.Y., Lee C.S., Watts C.K. and Sutherland R.L. (1989). Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int. J. Cancer 44, 744-752.
8. Half E., Tang X.M., Gwyn K., Sahin A., Wathen K. and Sinicrope F.A. (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62, 1676-1681.
9. Hulkko S.M. and Zilliacus J. (2002). Functional interaction between the pro-apoptotic DAP3 and the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 295, 749-755.
10. Hundertmark S., Buhler H., Rudolf M., Weitzel H.K. and Ragosch V. (1997). Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J. Endocrinol. 155, 171-180.
11. Ioannidis C., Papamichail M., Agnanti N., Garas J., Tsawdaroglou N. and Sekeris C.E. (1982). The detection of glucocorticoid receptors in breast cancer by immunocytochemical and biochemical methods. Int. J. Cancer 29, 147-152.
12. Jiang W., Zhu Z., Bhatia N., Agarwal R. and Thompson H.J. (2002). Mechanisms of energy restriction: effects of corticosterone on cell growth, cell cycle machinery, and apoptosis. Cancer Res. 62, 5280-5287.
13. Karmali R.A., Welt S., Thaler H.T. and Lefevre F. (1983). Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer 48, 689-696.
14. Kelly L.M., Hill A.D.K., Kennedy S. and Connolly E.M. (2003). Lack of prognostic effect of COX-2 expression in primary breast cancer on short-term follow-up. Eur. J. Surg. Oncol. 29, 707-710.
15. Kingsley-Kallesen M., Mukhopadhyay S.S., Wyszomierski S.L., Schanler S., Schutz G. and Rosen J.M. (2002). The mineralo-corticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol. Endocrinol. 16, 2008-2018.
16. Kino T. and Chrousos G.P. (2004). Glucocorticoid and mineralocorticoid receptors and associated diseases. Essays Biochem. 40, 137-155.
17. Krishnan A.V., Swami S. and Feldman D. (2001). Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J. Steroid. Biochem. Mol. Biol. 77, 29-37.
18. Lee Y.N., Lee H.Y., Lee Y.M., Chung H.Y., Kim S.I., Lee S.K., Park B.C. and Kim K.W. (1988). Involvement of glucocorticoid receptor in the induction of differentiation by ginsenosides in F9 teratocarcinoma cells. J. Steroid. Biochem. Mol. Biol. 67, 105-111.
19. Leo J.C., Guo C., Woon C.T., Aw S.E. and Lin V.C. (2002). Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 145, 1314-1321.
20. Lien H.C., Lu Y.S., Cheng A.L., Chang W.C., Jeng Y.M., Kuo Y.H., Huang C.S., Chang K.J. and Yao Y.T. (2006). Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J. Pathol. 209, 317-327.
21. Liu X.H. and Rose D.P. (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 56, 5125-5127.
22. Ma X., Yang Q., Wilson K.T., Kundu N., Meltzer S.J. and Fulton A.M. (2004). Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res. 6, 316-321.
23. Madam A.P. and DeFranco D.B. (1993). Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc. Natl. Acad. Sci. USA 90, 3588-3592.
24. Moran T.J., Gray S. and Mikosz C.A. (2000). The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60, 867-872.
25. Nass S.J and Davidson N.E. (1999). The biology of breast cancer. Hematol. Oncol. Clin. North. Am. 13, 311-332.
26. Osborne C.K., Monaco M.E., Kahn C.R., Huff K., Bronzert D. and Lippman M.E. (1979). Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res. 39, 2422-2428.
27. Qi M., Hamilton B.J. and DeFranco D.B. (1989). v-mos oncoproteins affect the nuclear retention and reutilization of glucocorticoid receptors. Mol. Endocrinol. 3, 1279-1288.
28. Ranger G.S., Jewell A., Thomas V. and Mokbel K. (2003). Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J. Surg. Oncol. 88, 100-103.
29. Ranger G.S., Thomas V., Jewell A. and Mokbel K. (2004). Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 24, 2349-2351.
30. Ristimäki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., Joensuu H. and Isola J. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62, 632-635.
31. Rolland P.H., Martin P.M., Jacquemier J., Rolland A.M. and Toga M. (1980). Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 64, 1061-1070.
32. Rubens R.D., Tinson C.L., Coleman R.E., Knight R.K., Tong D., Winter P.J. and North W.R. (1988). Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br. J. Cancer 58, 626-630.
33. Sasano H., Frost A.R., Saitoh R., Matsunaga G., Nagura H., Krozowski Z.S. and Silverberg S.G. (1997). Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res. 17, 2001-2007.
34. Schneider S.M., Offterdinger M., Huber H. and Grunt T.W. (1999). Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 58, 171-181.
35. Schrey M.P. and Patel K.V. (1995). Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br. J. Cancer 72, 1412-1419.
36. Schwartzman R.A. and Cidlowski J.A. (1994). Glucocorticoid-induced apoptosis of lymphoid cells. Int. Arch. Allergy Immunol. 105, 347-354.
37. Sephton S.E., Sapolsky R.M., Kraemer H.C. and Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer. Inst. 92, 994-1000.
38. Shim V., Gauthier M.L., Sudilovsky D., Mantei K., Chew K.L., Moore D.H., Cha I., Tlsty T.D. and Esserman L.J. (2003). Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 63, 2347-2350.
39. Traynor A. (1995). Recent advances in hormonal therapy for cancer. Curr. Opin. Oncol. 7, 572-581.
40. Uht R.M., Anderson C.M., Webb P. and Kushner P.J. (1997). Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 138, 2900-2908.
41. Van Steensel B., van Binnendijk E.P., Hornsby C.D., van der Voort H.T., Krozowski Z.S., Kloet E.R. and van Driel R. (1996). Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. J. Cell Sci. 109, 787-792.
42. Walsh D. and Avashia J. (2002). Glucocorticoids in clinical oncology. Cleve. Clin. J. Med. 59, 505-515.
43. Watanabe O., Shimizu T., Imamura H., Kinoshita J., Utada Y., Okabe T., Kimura K., Hirano A., Yoshimatsu K., Aiba M. and Ogawa K. (2003). Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res. 23, 3215-3221.
44. Wu W., Pew T., Zou M., Pang D. and Conzen S.D. (2005). Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem. 280, 4117-4124.
45. Wyllie A.H. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284, 555-556.
46. Zhang M.Z., Harris R.C. and McKanna J.A. (1999). Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc. Natl. Acad. Sci. USA 96, 15280-15285.
47. Zhang M.Z., Hao C.M., Breyer M.D., Harris R.C. and McKanna J.A. (2002). Mineralocorticoid regulation of cyclooxygenase-2 expression in rat renal medulla. Am. J. Physiol. Renal Physiol. 283, 509-516.
48. Zhou F., Bouillard B., Pharaboz-Joly M.O. and Andre J. (1989). Non-classical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol. Cell. Endocrinol. 66, 189-197.